The Cancer Vaccine Coalition, partnering with the V Foundation for Cancer Research, awarded $1 million to UT MD Anderson Cancer Center for a Phase II breast cancer recurrence trial. The INTERCEPT-HER2 study uses a blood-based circulating tumor DNA test to identify molecular signals of recurrence early, aiming to intervene before metastatic disease develops. Patients enrolled will receive a therapeutic cancer vaccine designed to train the immune system to recognize and destroy remaining cancer cells during a window where disease burden is lowest. The trial is led by Paula Pohlmann, professor of breast medical oncology at MD Anderson. The grant was supported by the Brian and Sheila Jellison Family Foundation and issued through CVC’s strategic granting partnership with the V Foundation.